DWK Life Sciences Completes Acquisition of Assem-Pak | Aluseal
5.5.2023 23:59:00 EEST | Business Wire | Press release
DWK Life Sciences (“DWK”), a leading global manufacturer and supplier of laboratory glassware, plasticware, and primary packaging solutions, has completed the acquisition of Assem-Pak | Aluseal (“Assem-Pak”), a U.S. company based in Vineland, New Jersey. Assem-Pak, which was founded 23 years ago and currently employs 110 people at their New Jersey facility, specializes in the production of premium rubber stoppers and aluminum seals as well as premium services such as washing, cleaning, assembling, and kitting of primary packaging for the Life Science market.
The acquisition will allow DWK to broaden its range of customizable packaging solutions for the Life Science industry segment, enabling it to support customers at every critical step of their development process. Assem-Pak also strengthens DWK’s value proposition of providing bundled solutions, allowing organizations to consolidate and simplify their complex supply chains.
DWK’s recent investments in its plants in Rockwood (U.S.) and Holzminden (Germany) have increased its manufacturing capability for glass vials across the U.S. and Europe. With the addition of Assem-Pak, DWK continues its expansion plan to further strengthen its presence in the Life Science packaging solutions market.
“I’m excited that Assem-Pak has joined the DWK family to enhance our vision of being a leading packaging solutions provider. Assem-Pak’s combination of manufacturing expertise and service offerings is a great addition to our already extensive global production and service footprint. This acquisition will allow DWK to capitalize on increasing demand for custom solutions to meet the complex needs of the Life Science industry,” said Armin Reiche, CEO of DWK Life Sciences.
Jeff Schempp, CEO of DWK Life Sciences LLC (North America) added: “The combination of Assem-Pak’s manufacturing capabilities in rubber stoppers and aluminum seals combined with DWK’s global market access makes this a perfect fit for both companies. We’re happy to have a great team join the DWK Group to help us achieve our objectives for years to come.”
About DWK Life Sciences
DWK Life Sciences is the leading global manufacturer and provider of precision labware as well as primary packaging solutions for Life Science Research, Applied Sciences and Diagnostics, and Pharmaceutical markets.
With over 35,000 products, the company’s offering includes the most comprehensive range of premium laboratory glassware together with a complementary portfolio of plastic products. They are manufactured at 12 global sites and marketed under the acclaimed brands DURAN®, WHEATON®, and KIMBLE®.
Worldwide, our 1,900 employees are dedicated to developing and delivering superior products and services to meet the highest expectations of customers in laboratories and production environments around the world. To learn more, visit www.DWK.com.
DWK Life Sciences is a portfolio company of One Equity Partners.
About One Equity Partners
One Equity Partners (“OEP”) is a middle market private equity firm focused on the industrial, healthcare, and technology sectors in North America and Europe. The firm seeks to build market-leading companies by identifying and executing transformative business combinations. OEP is a trusted partner with a differentiated investment process, a broad and senior team, and an established track record generating long-term value for its partners. Since 2001, the firm has completed more than 300 transactions worldwide. OEP, founded in 2001, spun out of JP Morgan in 2015. The firm has offices in New York, Chicago, Frankfurt and Amsterdam. For more information, please visit www.oneequity.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230505005451/en/
Contact information
Cortney Ecklor, Digital Marketing Manager
cortney.ecklor@dwk.com
phone: 865.399.6047
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom